E. Ziani

Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study.

P. van Damme, B. Soubeyrand, I. De Coster, 2015, Vaccine.

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months

T. Vesikari, F. Boisnard, T. Becker, 2017, The Pediatric infectious disease journal.

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

G. Icardi, T. Vesikari, F. Boisnard, 2016, Vaccine.

Integrated Safety Profile of a New Approved, Fully-liquid DTaP5-HB-IPV-Hib Vaccine.

G. Liu, G. Liu, J. Stek, 2019, The Pediatric infectious disease journal.

What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?

B. Fordham, B. Soubeyrand, A. Lloyd, 2015, Patient preference and adherence.

O-147a Assessment Of Preparation Time With Fully Liquid Versus Reconstituted Paediatric Hexavalent Vaccines. A Time And Motion Study

P. van Damme, B. Soubeyrand, I. De Coster, 2014, Archives of Disease in Childhood.